XM does not provide services to residents of the United States of America.
N
N

Novartis

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Europe before the bell: busy busy

LIVE MARKETS-Europe before the bell: busy busy Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com . EUROPE BEFORE THE BELL: BUSY BUSY There's plenty for investors to digest on Thursday, with earnings from Nvidia overnight and Novartis early Thursday, as well as geopolitics, the latest Trump appointments , bitcoin heading towards $100,000, and Indian billionaire Gautam Adani's indict
C
N
N
P
J
E
F
G

Novartis: launch of Morphosys drug by could be 2027 or later

Novartis: launch of Morphosys drug by could be 2027 or later FRANKFURT, Nov 21 (Reuters) - Novartis' NOVN.S CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data. "It will take us at least until 2027. It might take longer, depending on the safety topic.
N

Swiss stocks - Factors to watch on November 21

Swiss stocks - Factors to watch on November 21 ZURICH/GDANSK, Nov 21 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ZURICH INSURANCE GROUP AG ZURN.S Europe's fifth-largest insurer Zurich Insurance unveiled its targets for the next three years on Thursday, aiming to reach average annual growth of more than 9% in its core earnings per share.
N
S
J
Z
S

Novartis raises sales guidance until 2028

UPDATE 3-Novartis raises sales guidance until 2028 Adds details on Pluvicto, MorphoSys from paragraph 8 By Ludwig Burger FRANKFURT, Nov 21 (Reuters) - Novartis NOVN.S raised its medium-term sales guidance on Thursday to 6% annual growth through 2028, driven by momentum of launched drugs and the prospect of upcoming launches. The Swiss drugmaker was previously targeting mid-term currency-adjusted sales growth of at least 5% from 2023 to 2028. However, the company said it was still expecting 5% sa
N

Novartis raises annual sales guidance until 2028

Novartis raises annual sales guidance until 2028 FRANKFURT, Nov 21 (Reuters) - Novartis NOVN.S on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions. The Swiss drugmaker was previously targeting mid-term currency-adju
N

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.